Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FTKQW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,679
Award facts
- Contract value 100% obligated
- $5,678.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector units. This firm fixed-price delivery order, valued at $5,678.70, was executed on September 15, 2025, with an ultimate completion date of September 16, 2025, and carries no set-aside designation. The award represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.999 billion vehicle established to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing contracts for a diverse portfolio of medications and biologics including prescription drugs, over-the-counter medications, vaccines, and specialty pharmaceuticals. The company's strategic positioning as a woman-owned small business has enabled it to compete effectively in federal procurement markets while maintaining a robust history of pharmaceutical deliveries to military health facilities. This particular delivery order for Nucala, a biologic auto-injector used in respiratory treatment, exemplifies the company's role in supporting the Defense Department's medical supply requirements across its healthcare infrastructure.
Quick answers
Who was awarded contract SPE2DB25FTKQW?
SPE2DB25FTKQW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 15, 2025.
How much is contract SPE2DB25FTKQW worth?
The government has obligated $5,679 on SPE2DB25FTKQW.
Is contract SPE2DB25FTKQW an order under another contract?
Yes. SPE2DB25FTKQW is a delivery order under SPE2DB22D9112, an indefinite delivery contract.
Was contract SPE2DB25FTKQW competed?
The extent of competition for SPE2DB25FTKQW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award